1 Lu FM,Zhuang H.Management of hepatitis B in China.Chin Med J(Engl),2009, 122:3-4.
2 中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南(2010年版). 肝脏,2011, 16:2-16.
3 Liaw YF,Kao JH,Piratvisuth T,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.Hepatol Int,2012,6:531-561.
4 Buster EH,Schalm SW,Janssen HL.Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.Best Pract Res Clin Gastroenterol,2008,22:1093-1108.
5 Haria M,Benfield P.Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis.Drugs,1995, 50:873-896.
6 Reijnders JG,Perquin MJ,zhang N,et al.Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.Gastroenterology,2010,139:491-498.
7 Buster EH,Flink HJ,Cakaloglu Y,et al.Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.Gastroenterology,2008,135:459-467.
8 Schalm SW,Heathcote J,Cianciara J,et al.Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection:a randomised trial.Gut,2000,46:562-568.
9 Janssen H L,van Zonneveld M,Senturk H,et al.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.Lancet,2005,365:123-129.
10 Barbaro G,Zechini F,Pellicelli AM,et al.Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B.An Italian multicenter,randomized trial.J Hepatol,2001,35:406-411.
11 Lau GK,Piratvisuth T,Luo KX,et al.Peginterferon Alfa-2a, lamivudine,and the combination for HBeAg-positive chronic hepatitisB.N Engl J Med,2005,352:2682-2695.
12 慢性乙型肝炎联合抗病毒治疗专家委员会.慢性乙型肝炎联合抗病毒治疗专家共识.中华实验和临床感染病杂志:电子版. 2011,5:224-233.
13 Su WW,Hsu CW,Lee CM,et al.Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large, randomised, multicentre, double-blind, placebo-controlled study. J Hepatol,2014,60(Suppl):S47.
14 Enomoto M,Nishiguchi S,Tamori A,et al.Entecavir and interferon-a sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B.J Gastroenterol,2013,48:397-404.
15 Ouzan D,Pénaranda G,Joly H, et al.Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.J Clin Virol,2013,58:713-717.
16 Lampertico P,Vigano M,Di Costanzo GG,et al.Randomised study comparing 48 and 96 weeks peginterferon alpha-2atherapy in genotype D HBeAg-negative chronic hepatitis B.Gut,2013,62:290-298.
17 Boglione L,A. D'Avolio A,Cariti G,et al.Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV DNA with non-D genotypes.J Viral Hepat, 2013,20:e11-e19.
18 Ning Q,Han M,Sun Y,et al.Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial).J Hepatol,2014,61:777-784.
19 王磊,闫杰,张照华,等.拉米夫定治疗慢性乙型肝炎患者YMDD 变异及影响因素的研究.中华肝脏病杂志,2004,12:14-17.
20 Yokosuka O,Takaguchi K,Fujioka S,et al.Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection.J Hepatol, 2010,52:791-799.
21 邓琪. 干扰素α- 2b 联合恩替卡韦治疗慢性乙型肝炎的疗效观察.实用肝脏病杂志,2011,14:359-360.
22 李晶. α-干扰素联合恩替卡韦治疗慢性乙型肝炎早期疗效.肝脏,2012,17: 714-716.
23 李勇. 干扰素a-2b与恩替卡韦联合治疗慢性乙型肝炎患者疗效观察.中国实用医药, 2011,6:136-138.
24 Hagiwara S,Kudo M,Osaki Y,et al.Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.J Med Virol,2013,85:987-995.
25 Liu CJ,Wang CC,Yang SS,et al.Entecavir plus Peg-Interferon alfa-2a vs. Entecavir alone in the treatment of Hepatitis B e antigen-positive chronic Hepatitis B.J Hepatol,2013,58(Suppl 1):S308.
26 Wong GL,Wong VW,Chan HL,et al.Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B.[J] Viral Hepat.2014,21: 825-834.
27 杨德刚,缪晓辉.对乙型肝炎病毒共价闭合环状DNA的再认识.中华医学杂志,2007,87:1867-1870.
28 Brouwer WP,xie Q,Sonneveld MJ,et al.Adding Pegylated Interferon to Entecavir for HepatitisB e Antigen-Positive Chronic Hepatitis B:A Multicenter Randomized Trial (ARES Study).Hepatology,2015,61:1512-1522.
29 Xie Q, Zhou HJ,Bai XF,et al.A randomized, open-label clinical study of combined pegylated interferon alfa-2a (40KD) and entecavir treatment for hepatitis B“e” antigen-positive chronic hepatitis B.Clin Infect Dis, 2014,59:1714-1723.
30 Ning Q,Han MF,Sun YT,et al.Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial). J Hepatol, 2014,61:777-784.
31 聚乙二醇干扰素治疗核苷(酸)类似物经治慢性乙型肝炎专家组.聚乙二醇干扰素α治疗核苷(酸)类似物经治慢性乙型肝炎患者专家会议纪要.中华肝脏病杂志,2013,21:494-497.
32 Li GJ,Yu YQ,Chen SL,et al.Sequential combination therapy with peg-interferon leads to loss of HBsAg and HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with long-term entecavir treatment.Antimicrob Agents Chemother,2015,59:4121-4128.
33 Chen XF,Chen XP,Ma XJ,et al.Optimized strategy :sequential pegylatedinterferon α-2a therapy in entecavir-treatedpatientsCHB without satisfactory end-point led to HBeAg seroconversion.J Hepatol,2013,58(Suppl):S300-S301. |
